

Lupus Nephritis

A Study to Evaluate the Safety and Efficacy of Obinutuzumab Compared With Placebo in Participants With Lupus Nephritis (LN)

Trial Status
Completed

Trial Runs In
12 Countries

Trial Identifier
NCT02550652 2015-002022-39
WA29748

The source of the below information is the publicly available website ClinicalTrials.gov. It has been summarised and edited into simpler language.

Trial Summary:

This Phase II study will compare the efficacy and safety of obinutuzumab plus mycophenolate mofetil (MMF)/mycophenolic acid (MPA) with placebo plus MMF/MPA in participants with proliferative LN.

Hoffmann-La Roche
Sponsor

Phase 2
Phase

NCT02550652 2015-002022-39 WA29748
Trial Identifiers

Eligibility Criteria:

Gender
All

Age
≥18 Years & ≤ 75 Years

Healthy Volunteers
No
